Liver toxicity is one of the most common reasons for abandoning new drugs in development or withdrawing approved drugs from the market. Patel et al. show that in mice drug-induced liver injury can be limited by small-molecule inhibitor of the gap-junctional protein connexin 32.
- Suraj J Patel
- Jack M Milwid
- Martin L Yarmush